نتایج جستجو برای: vemurafenib
تعداد نتایج: 1054 فیلتر نتایج به سال:
Melanoma is molecularly and structurally heterogeneous, with some tumor cells existing under hypoxic conditions. Our cell growth assays showed that under controlled hypoxic conditions, BRAF(V600E) melanoma cells rapidly became resistant to vemurafenib. By employing both a three-dimensional (3D) spheroid model and a two-dimensional (2D) hypoxic culture system to model hypoxia in vivo, we identif...
Clinical vignette: A 49-year-old man with stage IV BRAFV600E-driven melanoma was initiated on twice-daily 960 mg of vemurafenib for treatment of progressive and recurrent subcutaneous metastatic disease of the left lower extremity. The patient's melanoma responded well to targeted BRAF inhibition. At treatment onset, hematologic parameters were all within normal limits; however, within three mo...
BACKGROUND BRAF inhibitors such as vemurafenib are a new family of biological drugs, recently available to treat metastatic malignant melanoma. METHODS We present the case of a 38-year-old man affected by metastatic melanoma who had been under treatment with vemurafenib for a few days. The patient suffered from sudden onset of abdominal pain due to intra-abdominal hemorrhage with profuse hemo...
Autophagy inhibition is a potential therapeutic strategy in central nervous system (CNS) tumors. The BRAF(V600E) mutation is known to affect autophagy. Our studies indicate CNS tumor cells with BRAF(V600E) mutant cells (but not wild type) display high rates of induced autophagy, are sensitive to autophagy inhibition, and display synergy when chloroquine is combined with the RAF kinase inhibitor...
INTRODUCTION Approved in 2011, vemurafenib is a selective serine/threonine kinase inhibitor directed against the V600E mutation in the BRAF gene. This drug is often used in dermatology as a targeted therapy for metastatic or unresectable melanomas, for which about 50% have this mutation. Other tumors possessing the V600E mutation are targets for this therapy. The commonly reported adverse effec...
Immune checkpoint inhibitors such as ipilimumab and targeted BRAF inhibitors have dramatically altered the landscape of melanoma therapeutics over the past few years. Agents targeting the programmed cell death-1/ligand (PD-1/PD-L1) axis are now being developed and appear to be highly active clinically with favorable toxicity profiles. We report two patients with BRAF V600E mutant melanoma who w...
Hairy-cell leukemia (HCL) is a lymphoproliferative disorder characterized by the presence of CD103-positive circulating B cells, pancytopenia and splenomegaly. HCL cases were recently shown to harbor a mutation at codon 600 of BRAF (V600E), suggesting that this genetic event represents a key driver of the disease. Recently, Dietrich et al. reported a case of refractory HCL treated with escalati...
BACKGROUND Since the majority of melanomas eventually become resistant and progress, combining selective BRAF inhibitors (BRAFi) with immunotherapies has been proposed to achieve more durable treatment responses. Here, we explored the impact of selective BRAFi on the hosts' immune system. PATIENTS AND METHODS Clinical data, whole blood counts (WBC) and serum lactate dehydrogenase (LDH) of 277...
Activating BRAF kinase mutations serve as oncogenic drivers in over half of all melanomas, a feature that has been exploited in the development of new molecularly targeted approaches to treat this disease. Selective BRAF inhibitors, such as vemurafenib, typically induce initial, profound tumor regressions within this group of patients; however, durable responses have been hampered by the emerge...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید